SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. Learn more about ARGX stock here.
Three drugs that inhibit the immunoglobulin G (IgG) neonatal fragment crystallizable receptor (FcRn) were approved to treat generalized myasthenia gravis (MG) in recent years: efgartigimod (Vyvgart), ...
Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune peripheral neuropathy primarily characterized by macrophage-mediated demyelination. Studies have identified that some patients ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data ...
4d
"I was fighting to survive": Patients still struggle with preauthorization despite promise of reform
Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, but patient advocates and medical providers remain skeptical.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
The market for drugs to treat the muscle-wasting disease generalised myasthenia gravis (gMG) is getting more crowded, and Argenx has just claimed an FDA approval that could expand its share. The US ...
Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for the would-be blockbuster as a treatment for generalised myasthenia gravis (gMG). It isn ...
A single intravenous ketamine infusion was safe and well-tolerated in older adults with mild cognitive impairment (MCI) and depression (MCI-D), with no serious adverse events (AEs) reported, a small ...
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results